Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Agios Pharmaceuticals Inc (NASDAQ:AGIO)

48.97
BATS BZX Real-Time Price
As of 9:57am ET
 +0.63 / +1.30%
Today’s Change
33.50
Today|||52-Week Range
126.35
-24.57%
Year-to-Date
Agios Pharmaceuticals (AGIO) Weak On High Volume
May 20 / TheStreet.com - Paid Partner Content
Agios Strikes Metabolic Immuno-Oncology Deal with Celgene
May 18 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close48.34
Today’s open49.10
Day’s range47.98 - 50.29
Volume727
Average volume (3 months)821,214
Market cap$1.8B
Dividend yield--
Data as of 9:57am ET, 05/25/2016

Growth & Valuation

Earnings growth (last year)-98.11%
Earnings growth (this year)--
Earnings growth (next 5 years)--
Revenue growth (last year)-9.55%
P/E ratioNM
Price/Sales41.10
Price/Book5.31

Competitors

 Today’s
change
Today’s
% change
EXAMExamWorks Group Inc-0.02-0.06%
NEONeogenomics Inc-0.06-0.68%
GNMKGenMark Diagnostics ...+0.04+0.58%
NVTAInvitae Corp-0.07-0.76%
Data as of 9:57am ET, 05/25/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$1.33
Annual revenue (last year)$59.1M
Annual profit (last year)-$117.7M
Net profit margin-199.14%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
David Paul Schenkein
Senior Vice President-Finance &
Contact Person
Glenn Goddard
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs